Gastroenteropancreatic neuroendocrine neoplasms

genes, therapies and models

Kenta Kawasaki, Masayuki Fujii, Toshiro Sato

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) refer to a group of heterogeneous cancers of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumors (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly differentiated). Although originally defined as orphan cancers, their steadily increasing incidence highlights the need to better understand their etiology. Accumulating epidemiological and clinical data have shed light on the pathological characteristics of these diseases. However, the relatively low number of patients has hampered conducting large-scale clinical trials and hence the development of novel treatment strategies. To overcome this limitation, tractable disease models that faithfully reflect clinical features of these diseases are needed. In this Review, we summarize the current understanding of the genetics and biology of these diseases based on conventional disease models, such as genetically engineered mouse models (GEMMs) and cell lines, and discuss the phenotypic differences between the models and affected humans. We also highlight the emerging disease models derived from human clinical samples, including patient-derived xenograft models and organoids, which may provide biological and therapeutic insights into GEP-NENs.

Original languageEnglish
JournalDisease models & mechanisms
Volume11
Issue number2
DOIs
Publication statusPublished - 2018 Feb 26

Fingerprint

Gene therapy
Neoplasm Genes
Genetic Therapy
Neoplasms
Organoids
Neuroendocrine Carcinoma
Neuroendocrine Cells
Inborn Genetic Diseases
Orphaned Children
Heterografts
Clinical Trials
Tumors
Phenotype
Cell Line
Cells
Incidence
Therapeutics

Keywords

  • GEP-NENs
  • Neuroendocrine cancer
  • Neuroendocrine tumor
  • Organoids
  • Rare disease modeling

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Gastroenteropancreatic neuroendocrine neoplasms : genes, therapies and models. / Kawasaki, Kenta; Fujii, Masayuki; Sato, Toshiro.

In: Disease models & mechanisms, Vol. 11, No. 2, 26.02.2018.

Research output: Contribution to journalReview article

@article{c35aedfbd0ed4dd4baed3b69272079b1,
title = "Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models",
abstract = "Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) refer to a group of heterogeneous cancers of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumors (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly differentiated). Although originally defined as orphan cancers, their steadily increasing incidence highlights the need to better understand their etiology. Accumulating epidemiological and clinical data have shed light on the pathological characteristics of these diseases. However, the relatively low number of patients has hampered conducting large-scale clinical trials and hence the development of novel treatment strategies. To overcome this limitation, tractable disease models that faithfully reflect clinical features of these diseases are needed. In this Review, we summarize the current understanding of the genetics and biology of these diseases based on conventional disease models, such as genetically engineered mouse models (GEMMs) and cell lines, and discuss the phenotypic differences between the models and affected humans. We also highlight the emerging disease models derived from human clinical samples, including patient-derived xenograft models and organoids, which may provide biological and therapeutic insights into GEP-NENs.",
keywords = "GEP-NENs, Neuroendocrine cancer, Neuroendocrine tumor, Organoids, Rare disease modeling",
author = "Kenta Kawasaki and Masayuki Fujii and Toshiro Sato",
year = "2018",
month = "2",
day = "26",
doi = "10.1242/dmm.029595",
language = "English",
volume = "11",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "2",

}

TY - JOUR

T1 - Gastroenteropancreatic neuroendocrine neoplasms

T2 - genes, therapies and models

AU - Kawasaki, Kenta

AU - Fujii, Masayuki

AU - Sato, Toshiro

PY - 2018/2/26

Y1 - 2018/2/26

N2 - Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) refer to a group of heterogeneous cancers of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumors (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly differentiated). Although originally defined as orphan cancers, their steadily increasing incidence highlights the need to better understand their etiology. Accumulating epidemiological and clinical data have shed light on the pathological characteristics of these diseases. However, the relatively low number of patients has hampered conducting large-scale clinical trials and hence the development of novel treatment strategies. To overcome this limitation, tractable disease models that faithfully reflect clinical features of these diseases are needed. In this Review, we summarize the current understanding of the genetics and biology of these diseases based on conventional disease models, such as genetically engineered mouse models (GEMMs) and cell lines, and discuss the phenotypic differences between the models and affected humans. We also highlight the emerging disease models derived from human clinical samples, including patient-derived xenograft models and organoids, which may provide biological and therapeutic insights into GEP-NENs.

AB - Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) refer to a group of heterogeneous cancers of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumors (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly differentiated). Although originally defined as orphan cancers, their steadily increasing incidence highlights the need to better understand their etiology. Accumulating epidemiological and clinical data have shed light on the pathological characteristics of these diseases. However, the relatively low number of patients has hampered conducting large-scale clinical trials and hence the development of novel treatment strategies. To overcome this limitation, tractable disease models that faithfully reflect clinical features of these diseases are needed. In this Review, we summarize the current understanding of the genetics and biology of these diseases based on conventional disease models, such as genetically engineered mouse models (GEMMs) and cell lines, and discuss the phenotypic differences between the models and affected humans. We also highlight the emerging disease models derived from human clinical samples, including patient-derived xenograft models and organoids, which may provide biological and therapeutic insights into GEP-NENs.

KW - GEP-NENs

KW - Neuroendocrine cancer

KW - Neuroendocrine tumor

KW - Organoids

KW - Rare disease modeling

UR - http://www.scopus.com/inward/record.url?scp=85054100790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054100790&partnerID=8YFLogxK

U2 - 10.1242/dmm.029595

DO - 10.1242/dmm.029595

M3 - Review article

VL - 11

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 2

ER -